PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri Sells 14,694 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCTGet Free Report) EVP Alaleh Nouri sold 14,694 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $49.97, for a total value of $734,259.18. Following the transaction, the executive vice president now owns 47,351 shares of the company’s stock, valued at approximately $2,366,129.47. The transaction was disclosed in a filing with the SEC, which is available at this link.

Alaleh Nouri also recently made the following trade(s):

  • On Wednesday, February 7th, Alaleh Nouri sold 5,306 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $49.95, for a total transaction of $265,034.70.
  • On Tuesday, January 9th, Alaleh Nouri sold 16,000 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $44.97, for a total transaction of $719,520.00.
  • On Thursday, December 14th, Alaleh Nouri sold 3,204 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $42.95, for a total transaction of $137,611.80.
  • On Wednesday, December 6th, Alaleh Nouri sold 6,096 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $39.96, for a total transaction of $243,596.16.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT opened at $49.94 on Friday. The company’s 50 day simple moving average is $44.07 and its 200 day simple moving average is $36.33. The company has a debt-to-equity ratio of 0.18, a current ratio of 8.91 and a quick ratio of 7.89. PROCEPT BioRobotics Co. has a 1 year low of $24.83 and a 1 year high of $50.48.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. SVB Leerink assumed coverage on shares of PROCEPT BioRobotics in a research report on Monday, October 16th. They issued an “outperform” rating and a $37.00 price target for the company. Truist Financial lifted their price target on shares of PROCEPT BioRobotics from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Wells Fargo & Company lifted their price target on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, January 9th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of PROCEPT BioRobotics in a research note on Monday, October 16th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $44.00.

Get Our Latest Stock Analysis on PROCEPT BioRobotics

Institutional Trading of PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc grew its stake in shares of PROCEPT BioRobotics by 4.5% during the fourth quarter. Legal & General Group Plc now owns 6,843 shares of the company’s stock worth $284,000 after buying an additional 295 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of PROCEPT BioRobotics by 5.8% during the fourth quarter. Amalgamated Bank now owns 5,804 shares of the company’s stock worth $243,000 after purchasing an additional 316 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of PROCEPT BioRobotics by 31.0% during the second quarter. Osaic Holdings Inc. now owns 1,430 shares of the company’s stock worth $51,000 after purchasing an additional 338 shares during the period. Credit Suisse AG lifted its holdings in shares of PROCEPT BioRobotics by 6.0% during the third quarter. Credit Suisse AG now owns 7,594 shares of the company’s stock worth $314,000 after purchasing an additional 430 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of PROCEPT BioRobotics by 5.7% during the fourth quarter. Principal Financial Group Inc. now owns 10,588 shares of the company’s stock worth $444,000 after purchasing an additional 568 shares during the period. Institutional investors own 79.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Recommended Stories

Insider Buying and Selling by Quarter for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.